Ex-Al­tim­mune chief Bill En­right lands CEO role at Vac­citech; Rea­ta poach­es Al­ny­lam CFO Man­meet Soni

→ Af­ter a stint con­sult­ing for Avidea Tech­nolo­gies, Bill En­right is back at the CEO game Vac­citech’s new chief. Like Al­tim­mune — which En­right led for 11 years — Vac­citech has a dual fo­cus on can­cer and in­fec­tious dis­eases. The ap­point­ment brings him from Bal­ti­more to Ox­ford, UK, where he will over­see piv­otal da­ta read­out from its lead in­fluen­za pro­gram. Mean­while, Tom Evans will tran­si­tion to the CSO post, steer­ing the sci­ence and R&D “that un­der­pin Vac­citech’s tech in­duc­ing CD8+ and CD4+ T cell re­spons­es against for­eign pathogens and tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER